Amneal Pharmaceuticals, Inc. AMRX Central nervous system — Net revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s central nervous system — net revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s central nervous system — net revenue?
- Amneal Pharmaceuticals, Inc. (AMRX) reported central nervous system — net revenue of $83.38M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s central nervous system — net revenue changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s central nervous system — net revenue increased by 23.3% year-over-year, from $67.61M to $83.38M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s central nervous system — net revenue?
- Over 2 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s central nervous system — net revenue has grown at a -28.8% compound annual growth rate (CAGR), from $658.31M to $333.42M.
- What does central nervous system — net revenue mean?
- This metric represents the total gross sales generated from the company's portfolio of pharmaceutical products specifically targeting central nervous system disorders, net of returns, rebates, and allowances. It serves as a key indicator of the commercial performance and market adoption of the company's specialty therapeutic offerings in this medical category. Tracking this revenue stream helps investors evaluate the growth trajectory and competitive positioning of the firm's proprietary specialty drug pipeline.